Dr. Peter Neustadt – Non – Executive Chairman, SomnoMed, Ltd.
Dr. Neustadt is a management consultant and entrepreneur with more than thirty years’ experience in building and improving public companies within the hospitality, media, property and finance sectors. He has previously worked for the global management consulting firm, McKinsey & Company and was an executive board member of Kerry Packer’s Consolidated Press Holdings (CPH).
Dr. Neustadt served on a number of public and private company boards including Cypress Lakes Group Limited, The Golden Door, CEL Limited, Network TEN, Advance Bank Limited, Trafalgar and Manboom Limited.
Mr. Neil Verdal-Austin – Chief Executive Officer, SomnoMed Ltd.
Mr. Verdal-Austin was appointed CEO in November 2018. He has more than twenty five years’ experience with various medical distribution and manufacturing companies where making a difference in people’s lives has become his passion. Prior to this appointment, Neil was SomnoMed’s CFO for 10 years and was instrumental in the company’s development from a small entity with revenues of less than $5 million and total staff of less than 50 people to a global company operating in 28 countries, generating some $70 million in revenues and employing over 500 people worldwide. He has not only excelled as CFO, but he also took direct management responsibility for the APAC region including Australia, New Zealand, Singapore and South Korea for four years from 2014 to 2018.
His experience includes systems development and implementation, business acquisitions, strategic planning, reporting and operations management. Prior to joining SomnoMed , Neil worked at LifeHealthcare, the largest Australian healthcare distributor of medical products and devices and served as CFO and a key stakeholder at the Orthomedics Group, a large medical distributor in South Africa. During that appointment, he was a key figure in the leadership team and instrumental in all commercial aspects of that business, its processes, acquisitions, financial performance and operational excellence.
Neil completed his studies at the University of Cape Town, South Africa and is a Chartered Accountant (Australia).
Terence A Flitcroft – Company Secretary
Mr. Flitcroft has been a Director of the company from 1995 until May 2003. He is a Chartered Accountant with broad commercial and financial experience and has acted as a director and company secretary for a number of private and public companies.
Terry provides company secretarial and accounting services to the Company on a contract basis. He is a Director of Winchester Associates Pty Limited, a licensed investment advisor.
Lee Ausburn – Non-Executive Director, M.Pharm., B.Pharm., Dip.Hosp.Pharm. (University of Sydney)
Lee has had a long career in the health industry, beginning as a pharmacist before joining Merck and Co. Inc., a global pharmaceutical company. During this period, she progressed through a range of roles, beginning in marketing before becoming responsible for reimbursement and pricing of Merck products in Australia.
In 1998 she moved into a regional role and was ultimately Vice President, Asia Merck & Co. Inc. responsible for the general management and strong growth of Merck organisations and their products across Asia reporting directly to the executive responsible for the geographic area in the US. During this time, Lee built businesses in a number of countries, often from the very beginning, planned and launched new products, liaised with regulatory authorities and government agencies and built and supervised management teams responsible for building Merck’s business in that part of the world. After leaving Merck in 2008, she has taken on a number of non-executive director roles.
She is a non-executive director of Australian Pharmaceutical Industries (API) Ltd and nib Health insurance.
In addition she is a member of two NSW government boards which are responsible for the implementation of the Garling recommendations to improve the quality of care in NSW hospitals- the Clinical Excellence Commission and the Agency for Clinical Innovation.
Hamish Corlett – Non-Executive Director
Hamish is a founder and director of TDM Growth Partners, a leading private investment firm specializing in long term investments in high growth companies globally. TDM made its first investment in SomnoMed in April 2010 and has been a substantial shareholder since October 2012.
Prior to TDM, Hamish worked as an investment manager at Caledonia Investments, a global fund manager. He has extensive experience in North America and Europe in addition to Australia.
Hamish holds a Bachelor of Commerce with Honours Class 1 (Accounting and Finance) from the University of Sydney and a Graduate Diploma of Counseling from the Australian College of Applied Psychologists.
Robert Scherini – Non-Executive Director
Rob is a past Managing Director for Johnson & Johnson Medical Australia/NZ and has held senior management positions both locally and internationally. He was posted for a number of years in J&J international headquarter in Brussels before returning to Australia where he was directly responsible for J&J’s medical device business in the APAC region. He has a strong track record of growing businesses and brings to the Board a wealth of experience in Sales & Marketing, Business Development, Finance, Operations and Supply, Legal, Human Resources and Information Technology.
Rob has a bachelor degree in Business and is a Certified Practicing Accountant (CPA). He was a Member of the Board of the Medical Technology Association of Australia (MTAA) for nine years. He has been a strong advocate of Human Resources Strategy and was recognised as Best HR Champion at the 2004 Australian HR Awards. In 2007 was awarded a Rotary International Fellowship for his assistance to the community.
More recently Rob has devoted his time to consulting and mentoring. He is a senior partner of a healthcare consultancy focused on Asia Pacific and a member of the Board of a large privately owned medical device company. Rob is also a member of the Executive Advisory Council of Nursing & Midwifery at the University of Technology, Sydney (UTS).